Genetically engineered mouse models have shown that the combinations with Pten ablation with mutations of Pik3ca [270], Arid1a [273], or KrasG12D [272] promote and aggressively develop invasive endometrial carcinomas, whereas solely PTEN loss does not or takes a long time to induce malignant tumors. The gene discussed is ARID1A; the disease is cancer.